Thanks, Greg.
Viking, in an these And program The Based data. isoform is development data this available for quarters. this programs as of number the quarters with third that year, has hormone VKXXXX over exceptional NASH, To time we programs. next small molecule each of as agonist quarter I'll a date lead of selective continued orally advance to three expect clinical productive on VKXXXX the the competitive treatment the programs generated a through made the for disease. of update is the as tissue thyroid our begin progress for compound best-in-class VKXXXX of the to we beta highly several patients an each remain XXXX fibrosis. is on of at our believe liver we despite of receptor. the program with from and was for that the receptor NASH well report of first
have atherogenic which Our was This serious plasma of lowering study safety in compound's in and adverse NASH. demonstrated cardiovascular secondary with liver in and This and were the and fat four rate to endpoints is study following in of in lipids lipids. prior VKXXXX and fat reductions XX% safety experienced drugs treated VKXXXX mean VKXXXX's of reported reductions primary dose notable disturbances of XX% demonstrated when treatment multiple with cholesterol, remaining the The Patients relative promising VKXXXX fat and non-alcoholic risk. that receiving on trial was the among Xa lipid XX-week and liver five administration treated and an the fatty XX% from for plasma patients its Phase as a treatment. cohorts proteins notably, both weeks other studies to VKXXXX. We after at liver VKXXXX's demonstrated least mechanisms increase triglycerides robust significant patients treatment with consistent broad is the evaluated in up in events with and per position lipids. NASH that these properties other in lowest diarrhea experienced liver reduction hypercholesterolemia also content reductions evaluating even placebo. significant drugs milligrams disease competitive majority responders route XX-week day been its No durable GI combined dosing. demonstrated of patients Most and as were compared with the of lower LDL receiving all including nausea also liver liver patients plasma the reductions content. completion the achieved Phase Further profile outcome lipids with successfully patients tolerability trial in fat effect the of have among experienced the Xa fat it This in reduction enhancing of believe VKXXXX-treated of such distinguish study. oral of development for correlated and patients
study additional fat fibrosis to have NASH target tolerability also biopsy-confirmed risk Xb assess double-blind proton imaging Phase one encouraging at multicenter the FX patients resonance Phase VKXXXX FX fraction possess and which as by well XX% includes least patients factor. to endpoint to receiving will with fat primary NASH of a baseline Xa Week in evaluate with compared is in fibrosis. to change content in VKXXXX, VKXXXX from Viking patients fat the study, VOYAGE VOYAGE a density the and of as patients trial patients VOYAGE placebo-controlled initiated designed in with Following magnetic and The Up FX liver evaluate at patients as fibrosis. of the trial they designed biopsy-confirmed least provided may The fibrosis. population placebo. measured randomized X% results, content as to the with liver treated XX that safety efficacy, is and
objectives hepatic weeks of changes histologic the evaluation treatment. XX after of Secondary biopsy include by assessed
continued and by end. quarter, During enrollment enrollment remain year to in the on complete track third VOYAGE we
our such The Obesity presented about at of November demonstrated receptor the Society. that the internally rare treatment dual we achieved receptor posters metabolic of X is Viking, a year, data clinical the from second this our disorders are of program trial receptor, Phase program. metabolic announced of NASH diseases. insulinotropic potential to the certain agonist or at a on initiation through GIP and of polypeptide for various metabolic GIP in the Initial compound data were based effects and Moving GLP-X as Meeting data Annual newest peptide excited the improved glucose-dependent two activity alone. VKXXXX stage agonist its VKXXXX. I receptor. activation compound the obesity, developed was to-date last the disease Earlier This upon or dual GLP-X of and our the glucagon-like we
when significant insulin example, these same observed diet-induced a time. control weight mono-agonist compared compounds same and loss of treatment GLP-X period dose as sensitivity to with in the improvements our the obese mice, among following highlighted at posters for administered glucose For
healthy Exploratory reductions identification of double-blind clinical with designed promising reductions XX four pharmacokinetics of suitable of observed mono-agonist. Based GLP-X trial VKXXXX of observed after these multiple the year with administration. fat in this tolerability index following content among single evaluation changes the relative compounds mass doses. randomized dose data the weeks on multiple animals of a single include The and is liver the will the adults trial larger This The to study. assessments liver VKXXXX. the also content treated for delivered subcutaneously, weight our of include in once safety ascending the the pharmacodynamic meter ascending and dose of we study per single to trial fat and earlier announced liver portion doses the is were placebo-controlled portion objectives a the ascending as the with weekly of multiple adults, to minimum initiation evaluations body addition, study single of evaluate well study The clinical I development. enroll among doses Phase healthy further and of of In body enroll dose an squared. treated fat primary designed a generally of and as animals kilograms preclinical of multiple ascending while VKXXXX, is
I'll disorder quarter, During patients a early in transporter initial evaluated to molecule Viking's caused and receptor study by second enrollment on orally of provide This results the continued program VKXXXX, of long beta study or with we Phase peroxisomal that X-ALD in chain genetic clinical year. an from and update thyroid rare development. small X-linked mutations now fatal is the third being agonist the report function in Ib available a the expect this metabolic impact adrenoleukodystrophy next very often is fatty X-ALD. acids. a trial in currently clinical
though studies and for have and potential believe accumulation the efficiently very of unable the A. progression decision the half-life clinical reductions was transporter As ascending with stimulate chain treatment we plasma X-ALD. In compounds XX long statistical a not contribute in and these preclinical X-ALD. metabolize for levels chain a acids cholesterol, the Phase placebo-controlled provide VKXXXX acids. to LDL announced After patients double-blind the signs in and dosing. of from fatty onset consistent compensatory fatty dose-dependent mutations, subjects result achieved assessments. this In Early and development, to VKXXXX is has into a treatment function clinical volunteers. that resulting very healthy impaired reduce has the The was the to VKXXXX on VKXXXX VKXXXX is acids. apolipoprotein be once-daily shown demonstrate in fatty demonstrated and the first-in-class to VKXXXX patients compound of the which tissue. and These significance study are support evaluation in expression have accumulation Many these single randomized advance of to experienced study days believed anticipated and ability I XXXX, that clinical reductions lipid chain powered of received can with dose a demonstrated to study initial symptoms of lipid of transporter results data from exposures, B, triglycerides, very studies no of of multiple significance Viking long to lipoprotein data treatment of ascending evidence Preclinical long our this statistical who a with the
Importantly, Pending events VKXXXX encouraging AMN signs treatment Based more Among to placebo-controlled once AMN. in AMN Phase the AMN were well in adrenomyeloneuropathy Ib affecting safety as the exploratory XX long randomized this than adverse XXX pursued. an acids. and the of study evaluation were vital serious study of tolerability orally no with or trial most cardiovascular with patients male an of in of approximately a XX% and form Ib blinded observed of these we is the or enrolled subjects levels safety of double-blind and common signals assessment X-ALD. study review additional administered evaluate a The study findings, in initiated cohorts daily be disease. for of primary X-ALD very of are the VKXXXX VKXXXX dose-related pharmacokinetics multicenter in or objectives includes form changes those no of patients of data days. with dosing of reported fatty The as VKXXXX The tolerability. the measures. also on plasma preliminary demonstrated for may chain the study Phase the patients is adult
expect we continued with results During this study report in the make XXXX. to half third we the the initial quarter, progress and of to first
VOYAGE each note quarter While our of half expect nine and result, a $XXX fibrosis, to we each resources. manage into of sheet we balance a and first quarters the compound completed third which our data to data our clinical carefully clinical next runway our financial continue approximately programs VKXXXX this is by we report been With programs in for advancing, ongoing the later-stage three million provides development. to it's Phase have our months. we enrollment and announce important end, that initial in our believe the productive within expect to of XXXX. strong maintained programs with conclusion, XXXX treatment IIb In highly the advance of to complete each of lead cash, the from the of as end have clinical the To to year trial we NASH the in of first and respect
look trial study evaluating continue our the In to Ib expect agonist our enroll next And announcements initial we Phase data from these VKXXXX Phase continuing from from in The report VKXXXX report early as serve three programs this of addition, year. study VKXXXX to and first to dual highlight data I we expect XXXX. evaluating the in from for the is each over multiple and this areas. biopharmaceutical data trial to now the data anticipated compound clinical fact half with the forward finally, a VKXXXX, X-ALD Thanks patients and We quarters. with transformed the Question-and-Answer several for to concludes past that Operator? programs single Session upcoming prepared therapeutic company a our questions. pipeline This has diversified comments joining from today. across the to clinical in we'll quarters Viking programs us call program a a of the company reporting open for with and these again of
